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Abstract
We report a case of bilateral cavo-ilio-femoral thrombosis in an adolescent with factor V
heterozygous mutation and transient antiphospholipid antibodies secondary Varicella infection.
The clinical significance of finding transient antiphospholipid antibodies in the sera of infectious
disease is unclear. We here report a case of bilateral cavo-ilio-femoral thrombosis in an adolescent
with newly diagnosed factor V heterozygous mutation and transient antiphospholipid antibodies
secondary to Varicella infection.
Introduction
Factor V Leiden is the most common cause of inherited
thrombophilia, accounting for 40 to 80% of cases. The
prothrombin gene mutation, deficiencies in protein S,
protein C, and antithrombin account for most of the
remaining cases [1,2]. The total incidence of an inherited
thrombophilia in subjects with a deep vein thrombosis
ranges from 24 to 37% overall, compared to about 10
percent in controls. Heterozygosity for the factor V Leiden
mutation accounts for 90 to 95% of cases of the activated
protein C (APC) resistance phenotype. A much smaller
number of homozygotes exist. Acquired conditions that
can influence first generation APC resistance assays
include elevated factor VIII levels, pregnancy, use of oral
contraceptive, and the presence of antiphospholipid
antibodies. The prevalence of heterozygosity for the factor
V Leiden mutation in Caucasians, including Europeans,
Jewish, Israeli, Arab, Canadian, and Indian populations,
ranges from 1 to 8.5%.
Antiphospholipid syndrome (APS) is a systemic auto-
immune disorder characterized by a combination of
arterial or venous thrombosis and recurrent fetal loss,
accompanied by elevated titers of antiphospholipid
antibodies (aPL), namely the lupus anticoagulant (LAC)
and anticardiolipin antibodies (aCL) [3,4]. Also the anti
beta2-GPI is among the most commonly detected
subgroups of aPL antibodies. The syndrome may occur
in isolation (primary APS) or in association with an
underlying systemic disease, particularly systemic lupus
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erythematosus (SLE) (secondary APS). Since the associa-
tion between antiphospholipid antibodies (aPL) and
syphilis was first described, many other viral, bacterial
and parasitic infections have been shown to induce
antiphospholipid antibodies, notably anticardiolipin anti-
bodies (aCL). A review of the literature shows that while
aCL occur frequently in viral infections, particularly in HIV
(49.75%), HBV (24%) and HCV (20%), it is very rarely
associated with anti-b2 glycoprotein I antibodies (anti-
b2GPI) and is not correlated with thrombosis risk or
hematological manifestations of APS. Concerning bacter-
ial infections, aCL is often present in leprosy (42.7%),
where it is frequently associated with the presence of anti-
b2GPI (44.8%), and in syphilis infections (8 to 67%),
though without correlation with thrombotic events [5].
Case presentation
We report a case of 16-year-old male from Romania with
bilateral cavo-ilio-femoral thrombosis who recently recov-
ered from Varicella infection. The patient had not suffered
lack of mobility during the acute viral illness.
Several days after recovery from the infection, the patient
reached the emergency department referring strangury, an
increasing lumbar pain irradiating to the left leg, and
claudication. An abdominal Doppler ultrasound was
performed which demonstrated complete thrombosis of
the inferior vena cava up to the renal veins, with
involvement of the iliac and femoral veins bilaterally.
Chest and abdominal CT scans confirmed the bilateral
cavo-ilio-femoral thrombosis and excluded the presence
of pulmonary thromboemboli. While awaiting laboratory
results for thromphylic screening, anticoagulant therapy
was started with progressive physical recovery. The
thrombophylic screening (including homocysteine, lupus-
like anticoagulants, Protein C, Protein S, plasminogen, IgG
and IgM anticardiolipin and anti-b2-glycoprotein I)
demonstrated the presence of IgM anti-cardiolipin anti-
bodies (30.5 MPL), IgM anti-b2-glycoprotein I antibodies
(60 U/ml), and heterozygosis for mutation of the Factor
Leiden gene. Threemonths later the aPL antibodies were no
longer detectable.
Discussion
The appearance of antiphospholipid antibodies during
viral infections (especially parvovirus B19, cytomegalo-
virus, Varicella zoster virus, and HIV) is well documented
and is generally considered transient and not associated to
the progression towards an APS. However, the develop-
ment of thrombotic events during important viral and
bacterial infections is not infrequent.
Mutations in the Factor V gene, along with those in the
prothrombin gene, are the most common causes of
hereditary thrombophilia. The risk of thrombotic events
shows an 80 fold increase in subjects affected homozygote
mutations in Factor V when compared to that of healthy
subjects. The risk is 7 fold higher in those subjects affected
by heterozygote mutations. As a result, only about 10% of
subjects with the heterozygote mutation develops at least
on thrombotic event in his or her lifetime.
Several cases of thrombosis post-Varicella infection have
been reported, but only one case of ilio-femoral throm-
bosis post-Varicella infection in a patient with factor V
mutation is present in literature [5]. Uthman et al reported
the case of a 16-year-old boy who developed APS 1 week
after the occurrence of chickenpox [6]. He presented with
acute right ilio-femoro-popliteal deep vein thrombosis
(DVT) [7]. IgM and IgG aCL antibodies were both positive
on admission. IgM aCL antibodies remained positive 6
weeks later, which suggests their role as a predisposing
factor for DVT. Manco-Johnson et al [8], in a study
investigating the cause of purpura fulminans, dissemi-
nated intravascular coagulation, or thrombosis in 7
children with Varicella, reported the association of
thrombosis with the presence of aPL antibodies in
Varicella infections. Moreover, the investigators found all
the children to have a LAC and acquired protein S
deficiency. In addition, 4 of the patients had aPL or aCL
antibodies. Peyton et al [9] also reported the cases of 2
men with Varicella pneumonia who had profound lower
extremity ischemia caused by thrombosis of the profunda
femoris and tibial arteries. Both patients had free protein S
deficiency. IgG and IgM aPL antibodies were present in
one, whereas the other had evidence of the LAC. In
addition, Barcat et al [10] reported a case of DVT in an
adult with Varicella. Although there was no evidence of
thrombophilia, a transient significant level of aPL anti-
bodies and LAC were observed.
Conclusions
In conclusion, the clinical significance of finding transient
aCL and anti-b2-GPI antibodies in the sera of infectious
disease remains unknown. In some patients, these aPL
anti-b2-GPI antibodies are transient and disappear within
2 or 3 months. In some susceptible individuals, they raise
the question of whether infections may be a trigger for the
development of aPL and anti-b2-GPI antibodies which
may consequently activate a cascade of prothrombotic
events [10]. In our case, it is thus possible that the aPL
antibodies developed during the Varicella-infection may
have acted as a prothrombotic trigger in a case of
pre-existing hereditary thrombophilia which may have
otherwise remained undiagnosed. Consequently, greater
caution is warranted in the monitoring of patients with
inherited thrombophilia during infection, in order to
prevent possible significant and life-threatening thrombo-
tic complications.
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